New Findings from Hanyang University Hospital Yields New Data on Rheumatoid Arthritis [Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 ...]
By a News Reporter-Staff News Editor at Health & Medicine Week Investigators discuss new findings in Autoimmune Diseases and Conditions - Rheumatoid Arthritis. According to news originating from Seoul, South Korea, by NewsRx correspondents, research stated, "To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in patients with rheumatoid arthritis (RA) for an additional six infusions. This open-label extension study recruited patients with RA who had completed the 54-week, randomised, parallel-group study comparing CT-P13 with RP (PLANETRA; NCT01217086)."
Our news journalists obtained a quote from the research from Hanyang University Hospital, "CT-P13 (3 mg/kg) was administered intravenously every 8 weeks from weeks 62 to 102. All patients received concomitant methotrexate. Endpoints included American College of Rheumatology 20% (ACR20) response, ACR50, ACR70, immunogenicity and safety. Data were analysed for patients who received CT-P13 for 102 weeks (maintenance group) and for those who received RP for 54 weeks and then switched to CT-P13 (switch group). Overall, 302 of 455 patients who completed the PLANETRA study enrolled into the extension. Of these, 158 had received CT-P13 (maintenance group) and 144 RP (switch group). Response rates at week 102 for maintenance versus switch groups, respectively, were 71.7% vs 71.8% for ACR20, 48.0% vs 51.4% for ACR50 and 24.3% vs 26.1% for ACR70. The proportion of patients with antidrug antibodies was comparable between groups (week 102: 40.3% vs 44.8%, respectively). Treatment-emergent adverse events occurred in similar proportions of patients in the two groups during the extension study (53.5% and 53.8%, respectively)."
According to the news editors, the research concluded: "Comparable efficacy and tolerability were observed in patients who switched from RP to its biosimilar CT-P13 for an additional year and in those who had long-term CT-P13 treatment for 2 years."
For more information on this research see: Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Annals of the Rheumatic Diseases, 2016;76(2):355-363. (BMJ Publishing Group - group.bmj.com/; Annals of the Rheumatic Diseases - ard.bmj.com/)
The news correspondents report that additional information may be obtained from D.H. Yoo, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea. Additional authors for this research include N. Prodanovic, J. Jaworski, P. Miranda, E. Ramiterre, A. Lanzon, A. Baranauskaite, P. Wiland, C. Abud-Mendoza, B. Oparanov, S. Smiyan, H. Kim, S.J. Lee, S. Kim and W. Park (see also Autoimmune Diseases and Conditions - Rheumatoid Arthritis).
Keywords for this news article include: Asia, Seoul, South Korea, Rheumatoid Arthritis, Joint Diseases and Conditions, Autoimmune Diseases and Conditions, Musculoskeletal Diseases and Conditions.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC